Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

New generation of weight loss medications offer promise — but at a price

Excitement is building about a new generation of drugs that tout the ability to help adults with excess weight shed more pounds than older drugs on the market.

Tribune News Service

3 Names It Wouldn’t Hurt to Stock up On

Despite the Fed’s continued hawkish stance, the September inflation report came in hotter than expected, raising the possibility of another aggressive interest rate hike in November. However, it could be smart to keep investing in quality stocks to benefit from their rebound. We think Microsoft (MSFT), Eli Lilly (LLY), and…

StockNews.com

Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's Opportunity

Biogen could easily take on Roche and Eli Lilly in Alzheimer's treatment, an analyst said Thursday as he upgraded Biogen stock.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Amgen, The Big Name You Need To Know Going Up Against Novo, Lilly In Obesity Treatments

Amgen stock surged Tuesday on a reportedly bullish call for its experimental obesity treatment — a potential rival to Novo and Lilly.

Investors Business Daily

The Best Mutual Funds Invest Huge Sums In These 24 Stocks

As the market tries to rebound, the best mutual funds bet big on 24 stocks including Vertex, Lilly and Enphase.

Investors Business Daily

One Of Eli Lilly's Most Anticipated Drugs Could Hit The Market Next Year

Eli Lilly said Thursday it plans to begin the process of asking the FDA to approve its obesity treatment. LLY stock rose on the news.

Investors Business Daily

Dow Jones Futures Fall As Treasury Yields Rebound; Eli Lilly Leads 7 Bullish Stocks

Dow Jones futures fell as Treasury yields rebounded, signaling Wednesday's rally may be short-lived. Eli Lilly leads some bullish stocks.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Elon Musk Twitter Case Deposition Delayed, FTX US Goes Shopping, Spotify's Analyst Sees Audiobooks Immaterial: Top Financial Media Stories Tuesday, Sept. 27

Bloomberg

Benzinga

S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market

S&P 500 giant Eli Lilly leads five medical stocks setting up and showing relative strength in the ongoing bear market.

Investors Business Daily

IBD Stock Of The Day: Could 'The Biggest Drug Ever' Drive Eli Lilly Stock Even Higher?

Eli Lilly is the IBD Stock Of The Day as investors watch the company's obesity and Alzheimer's drugs, which could help shares skyrocket.

Investors Business Daily

The 'Transformative' Eli Lilly Drug That Could Top $25 Billion In Annual Sales

Eli Lilly's blockbuster potential diabetes drug Mounjaro is "de-risked and transformative," an analyst said Thursday as he updated LLY stock.

Investors Business Daily

Another reason not to work in Indiana

Eli Lilly and Co. was quick to understand just how bad a near abortion ban can be on business.

Chicago Sun-Times

Eli Lilly says Indiana abortion law forces hiring out-of-state

Eli Lilly & Co., one of Indiana’s largest employers, said the state’s freshly passed restrictions on abortion would force the drugmaker to “plan for more employment growth outside our home state.”

Tribune News Service

Major Indiana employer speaks out on state’s near-total abortion ban and vows to look outside state for ‘employment growth’

Pharmaceutical giant Eli Lilly is headquartered in Indianapolis and employs more than 10,000 people in the state

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review

The stock market rally had mixed action, with the Nasdaq and small caps rising while the S&P 500 and oil prices fell.

Investors Business Daily

Eli Lilly Slashes Profit Outlook After 'Significantly' Missing Second-Quarter Forecasts

Eli Lilly slashed its 2022 earnings outlook Thursday after "significantly" missing forecasts, leading LLY stock to crumble.

Daily Mirror

Kerry Katona wants daughter Lily, 19, to have baby as she's worried about dying

Kerry says her “health anxiety” causes her to constantly worry about dying young and she would love for her teenage daughter Lilly to have a child of her own

Investors Business Daily

Eli Lilly Stock Nears A New Buy Point

Pharmaceuticals giant Eli Lilly has formed a three-weeks tight pattern within the buy zone of flat base just before earnings.

Get all your
news in one place.

100’s of premium titles.
One news app.

Los Angeles Times

Michael Hiltzik: As professionals flee antiabortion policies, red states face a brain drain

A few days ago, a university headhunter reached out to Elizabeth T. Jacobs, a professor of epidemiology at the University of Arizona, to gauge her interest in moving to a leading university in Texas.

Benzinga

Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients

Sanofi SA (NASDAQ:SNY) said that uninsured diabetes patients in the U.S. will pay no more than $35 for a 30-day supply of insulin, down from $99. Sanofi said the new price would be effective from July 1. The announcement from Sanofi follows House passage (232-193) of the monthly cap in March, with just 12…

Investors Business Daily

Dow Jones Futures Jump, Bitcoin Above $20,000; Beware The Bear Market

Futures rose as Bitcoin rebounded. It's a bear market, so stay safe. Tesla rival BYD is among a few stocks setting up.

Benzinga

Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy

Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration.

Investors Business Daily

We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit

A group of pharmaceutical stocks are climbing as they pivot their diabetes drugs to help treat obesity. A potential multibillion-dollar market beckons them.

Benzinga

In Eli Lilly's Lebrikizumab Atopic Dermatitis Study, Majority Of Patients Maintained Skin Clearance At One Year

Eli Lilly And Co (NYSE:LLY) announced topline results from one-year analyses of the efficacy and safety of lebrikizumab for moderate-to-severe atopic dermatitis (AD). The new findings from the Phase 3 trials (ADvocate 1 and 2) showed that 8/10 of patients who achieved clinical response with lebrikizumab monotherapy at 16 weeks maintained skin clearance…

Investors Business Daily

Eli Lilly Flirts With Buy Point On A 'Flawless' Update For Its Diabetes-Turned-Obesity Drug

Eli Lilly delivered a promising update for its experimental obesity treatment over the weekend, leading LLY stock to pop Monday.

1 … 12 13 14 15

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.